Here is Think IP Strategy’s weekly selection of top Pharma & Biotech intellectual property news breaking in the blogosphere and internet.

Highlights this week included:

2nd Circuit denies en banc reconsideration in Cipro case: In re Ciprofloxacin Antitrust Litigation (Patent Docs) (FDA Law Blog) (IPBiz)

Please join the discussion by adding your comments on any of these stories, and please do let us know if you think we’ve missed something important, or if there is a source you think should be monitored.

General

Access to healthcare – is it really such a big IP issue? (IP Think Tank)

WIPO and patent exclusions: Public health and medical methods (Spicy IP)

Wall Street Journal article under fire – access to drugs – what’s the problem? (Afro-IP)

Africa: Giving consumers power in the battle against counterfeits (Afro-IP)

Australia: Review Four Corners’ ‘Body Corporate’ program on gene patenting (Patentology)

India: Roche and Novartis, finally, manage to defend their patents in oppositions filed by Cipla (Spicy IP)

South Africa: San people push for new legislation – demand protection for indigenous knowledge and IP including medicinal remedies derived from plants including Hoodia (Afro-IP)

US: PHOSITA: Flogging a dead horse – CAFC ruling in Goeddel v Sugano (Patent Baristas) (Patent Docs)

US: Yeda seeks review of BPAI decision awarding priority to Abbott in interference matter (Patent Docs)

Products

Actos (Pioglitazone) – US: Takeda files patent infringement complaint following Para IV certification filing by Synthon (Patent Docs)

Angiomax (Bivalirudin) – US: All eyes are on APP’s intervention motion as the government bows out of Angiomax PTE litigation: The Medicines Company v Kappos (FDA Law Blog)

Aricept (Donepezil) – US: Eisai’s motion to dismiss granted in Aricept suit with Apotex (Patent Docs)

Azor, Benicar, Benicar HCT (Olmesartan medoxomil) – US: CAFC: Mylan fails to establish prima facie case of obviousness: Daiichi Sankyo Co. v Matrix Laboratories, Ltd (Patent Docs)

Boniva (Ibandronate) – US: Hoffmann-La Roche files patent infringement complaint against Orchid in response to Para IV certification (Patent Docs)

Cipro (Ciprofloxacin) – US: 2nd Circuit denies en banc reconsideration in Cipro case: In re Ciprofloxacin Antitrust Litigation (Patent Docs) (FDA Law Blog) (IPBiz)

Combigan (Brimonidine/Timolol) – US: Allergan files patent infringement complaint against Watson following Para IV certification (Patent Docs)

Effexor (Venlafaxine) – US: Wyeth files patent infringement complaint following Dr Reddy’s Para IV certification filing (Patent Docs)

Gemzar (Gemcitabine) – BIO files amicus brief supporting Eli Lilly petition for en banc rehearing of Sun v Eli Lilly (Holman’s Biotech IP Blog)

Latisse (Bimatoprost) – US: Allergan files patent infringement complaint against Apotex in response to Para IV certification (Patent Docs)

Luvox (Fluvoxamine) – US: Jazz Pharmaceuticals and Anchen settle Luvox patent litigation (Patent Docs)

Meridia, Reductil, Sibutrex (Sibutramine) – Australia: Federal Court again rejects ‘obvious to try’: Abbott GMBH & Co. KG v Apotex Pty Ltd (No 2) (Patentology)

MoviPrep – US: Salix and Norgine settle with Novel in patent dispute over MoviPrep (Patent Docs)

Nexavar (Sorafenib) – India: Nexavar patent infringement suit before Delhi HC goes directly to trial: Bayer v Cipla (Spicy IP)

Simcor (Niacin/Simvastatin) – US: Abbott files patent infringement suit against Teva following Para IV challenge (Patent Docs)

Vancocin (Vancomycin) – US: ViroPharma sues FDA over generic Vancocin; alleges that FDA violated the APA in effectively amending bioequivalence regulations (FDA Law Blog)

Zetia (Ezetimib) – US: Schering files patent infringement complaint against Teva following Para IV certification filing (Patent Docs)